Fertility Testing in 2026: Understanding Your Options Before Starting Treatment
Before beginning any fertility treatment, a thorough evaluation is essential. Fertility testing in 2026 has become more precise, providing a clearer picture of both partners’ reproductive health and enabling more targeted treatment planning. Understanding what the standard workup involves—and why each component matters—helps patients approach the process with realistic expectations.
For Women: Key Components of the Fertility Evaluation
The female fertility evaluation typically covers several areas:
Ovarian Reserve Assessment: This is one of the most important initial tests. Anti-Müllerian hormone (AMH) is a blood test that reflects the pool of remaining eggs. Antral follicle count (AFC), measured by ultrasound, provides a direct visual assessment of follicle number. Together, these tests give a reliable picture of how the ovaries are likely to respond to stimulation. Lower reserve does not preclude pregnancy, but it affects treatment planning and prognosis.
Hormonal Panel: Testing FSH (follicle-stimulating hormone), LH (luteinizing hormone), and estradiol on cycle day 2 or 3 provides additional information about ovarian function. Thyroid function and prolactin levels are also typically assessed, as abnormalities in these hormones can affect ovulation and implantation.
Uterine Evaluation: A sonohysterogram or hysteroscopy examines the uterine cavity for fibroids, polyps, or structural abnormalities that could interfere with implantation. An HSG (hysterosalpingogram) or laparoscopy evaluates tubal patency—whether the fallopian tubes are open and functional.
Additional Testing: Depending on history and initial results, additional assessments may include thrombophilia testing, infectious disease screening, genetic carrier testing, and evaluation for autoimmune factors that could affect implantation.
For Men: Semen Analysis and Beyond
Male factor infertility contributes to approximately half of all infertility cases, making thorough male evaluation equally important.
Semen Analysis: The core test assesses sperm count, motility (movement), morphology (shape), and volume. Results outside normal ranges indicate areas for further investigation.
Hormonal Evaluation: When semen parameters are abnormal, hormonal testing (FSH, testosterone, LH, and prolactin) can identify treatable underlying causes such as hypogonadism or hyperprolactinemia.
Genetic Testing: For men with very low sperm counts (severe oligospermia) or no sperm (azoospermia), karyotype analysis and Y-chromosome microdeletion testing can identify genetic causes that affect treatment planning and counseling.
Translating Results Into a Treatment Plan
The evaluation findings collectively inform treatment recommendations. Some diagnoses point clearly toward specific approaches—severe tubal disease typically means IVF; significant male factor may mean IVF with ICSI; normal evaluations in a young patient may support IUI trials. In cases where evaluation results are within normal ranges yet pregnancy has not occurred, unexplained infertility is the diagnosis—and this, too, has established treatment pathways.
The Fertility Institute of San Diego conducts comprehensive fertility evaluations for both partners as the foundation of individualized treatment planning. Working with Dr. Minoos Hosseinzadeh, patients receive a complete assessment before any treatment decision is made, ensuring that the recommended approach is grounded in their actual clinical picture. If you are beginning your fertility journey, scheduling a fertility evaluation is the appropriate first step in 2026.
Roderick Smith is a writer, blogger, and business owner. He has been writing for over 5 years and his blog naouelmoha.net offers valuable information about the business, health, law, and the latest technology. Roderick lives in Nashville with his wife and three children.
